A Phase 2 Study Of Bevacizumab And Interferon-Alpha-2b In Metastatic Malignant Melanoma.

Trial Profile

A Phase 2 Study Of Bevacizumab And Interferon-Alpha-2b In Metastatic Malignant Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Interferon alpha-2b (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Mar 2016 Patients are differentiated based on dose of Interferon Alfa on different days along with change in the time frame of primary end points as per ClinicalTrials.gov record.
    • 10 Apr 2013 Planned end date changed from 1 Sep 2002 to 1 Apr 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top